Live Analyst Rating Changes 1526 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Matt Larew
WB
Matt Larew
William Blair
Wall Street Analyst
★★★★☆
#434
on 13Foresight · ranked by our own returns
65%
Success Rate
+9.9%
Average Return
17 of 26 calls profitable · -3766.6% vs benchmark
🔒 3-year track record is Pro. Showing 1-year — upgrade.
📈 Across the calls we could measure, roughly 65% of Matt Larew's ratings turned a profit when each position was held for 1 year — averaging +9.9% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

82 Buy 30 Hold 4 Sell
Matt's Stock Coverage 24 ratings · 2026-06-21
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return
TMO
Thermo Fisher
 Jun 12, 2026 BUY Strong Buy
+26.8% avg upside
38 analysts
 — -1.5%
STVN
Stevanato Group
 Jun 10, 2026 BUY Strong Buy
+53.7% avg upside
13 analysts
 — -0.7%
OPCH
Option Care Health
 Jun 01, 2026 BUY Strong Buy
+34.7% avg upside
20 analysts
 — +6.1%
TWST
Twist Bioscience
 May 26, 2026 BUY Strong Buy
-26.4% avg upside
14 analysts
 — +30.9%
WST
West Pharmaceutical Services
 May 20, 2026 BUY Strong Buy
+6.5% avg upside
17 analysts
 — +7.9%
RGEN
Repligen
 May 14, 2026 BUY Strong Buy
+28.4% avg upside
25 analysts
 — +27.7%
MXCT
MaxCyte
 May 13, 2026 HOLD Buy
+230.6% avg upside
5 analysts
 — +2.0%
DNA
Ginkgo Bioworks Holdings
 May 11, 2026 SELL Sell
-14.6% avg upside
5 analysts
 — -5.8%
MRVI
Maravai Lifesciences Holdings
 May 08, 2026 HOLD Strong Buy
+174.4% avg upside
17 analysts
 — -14.4%
TXG
10x Genomics
 May 08, 2026 BUY Buy
-27.9% avg upside
18 analysts
 — +47.0%
TECH
Bio-Techne
 May 07, 2026 BUY Strong Buy
+38.3% avg upside
21 analysts
 — +10.3%
TKNO
Alpha Teknova
 May 07, 2026 BUY Strong Buy
+173.6% avg upside
7 analysts
 — +29.5%
MASS
908 Devices
 May 06, 2026 BUY Strong Buy
+24.4% avg upside
4 analysts
 — -14.4%
WAT
Waters
 May 05, 2026 BUY Buy
+3.6% avg upside
30 analysts
 — +4.2%
ATR
AptarGroup
 May 01, 2026 HOLD Buy
+14.4% avg upside
14 analysts
$119.00
1.04% Downside
 -0.6%
AVTR
Avantor
 Apr 29, 2026 HOLD Buy
+49.6% avg upside
26 analysts
 — +20.5%
DHR
Danaher
 Apr 22, 2026 BUY Strong Buy
+21.9% avg upside
45 analysts
 — -3.4%
CRL
Charles River Labs
 Oct 11, 2025 BUY Strong Buy
+11.9% avg upside
34 analysts
 — +6.9%
USPH
US Physical Therapy
 Oct 08, 2024 HOLD Strong Buy
+44.4% avg upside
12 analysts
 — +19.2%
NL:LIGHT
Signify NV
 Aug 22, 2022 BUY Buy
+10.3% avg upside
10 analysts
 — ·
INNV
InnovAge Holding
 Sep 22, 2021 HOLD Sell
-18.6% avg upside
12 analysts
 — -27.3%
DVA
DaVita
 Sep 11, 2019 HOLD Hold
-23.0% avg upside
17 analysts
 — +47.2%
LH
Labcorp Holdings
 Dec 03, 2018 BUY Strong Buy
+1.8% avg upside
36 analysts
 — +15.0%
EHC
Encompass Health
 Nov 21, 2017 BUY Strong Buy
+13.4% avg upside
22 analysts
 — +48.5%
🔒 19 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Matt Larew — Frequently Asked Questions
How accurate are Matt Larew's stock ratings?
Based on the calls 13Foresight could measure, about 65% of Matt's ratings were profitable over a one-year hold, with an average return of +9.9% per rating, or -3766.6% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Matt ranked on 13Foresight?
Matt Larew is currently ranked #434 with a 4-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Matt cover?
Matt most recently has ratings on TMO, STVN, OPCH, TWST, WST, RGEN, MXCT, DNA, MRVI, TXG, TECH, TKNO and 12 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.